scholarly journals DROP SIZE OF COMMONLY USED ANTIGLAUCOMA EYE DROPS

2021 ◽  
pp. 277-278
Author(s):  
Shipra Gupta ◽  
Sutapa Das ◽  
C. Dinesh M. Naidu ◽  
Tushar Vashisht
Keyword(s):  
Adverse Effects ◽  
Patient Compliance ◽  
Drop Size ◽  
Eye Drops ◽  
Adherence To Therapy

Introduction:Many factors affect the adherence to therapy in glaucoma patients.One of these factors being size of the drop administered. Big drop size not only leads to early exhaustion of medication but also causes unwanted adverse effects. This study was done to find out the drop size of commonly used anti-glaucoma eye drops. Material and methods: Four commonly used eye drops were included in the study:Timolol 0.5%,Brinzolamide 1%,Brimonidine 0.2% and Bimatoprost 0.03% eye drops.Three bottles of each drug was taken.The bottles were emptied in a 10 ml graduated cylinder drop by drop.The total volume and number of drops were noted,and drop size was calculated.Result:The drop size for Timolol, Brinzolamide, Brimonidine and Bimatoprost was 38.62 µl, 43.09 µl, 45.87 µl and 39.19 µl respectively. Conclusion:The drop size of anti-glaucoma medications can further be reduced and this may lead to improved patient compliance and reduce the adverse effects

Managing Primary Open-angle Glaucoma – Ocular Tolerability, Compliance, Persistence and Patient Outcomes

2009 ◽  
Vol 03 (01) ◽  
pp. 19 ◽  
Author(s):  
Anton Hommer ◽  
Keyword(s):  
Adverse Effects ◽  
Patient Compliance ◽  
Vision Loss ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Tolerability Profile ◽  
Eye Drops ◽  
Open Angle ◽  
The Individual ◽  
Ocular Tolerability

Primary open-angle glaucoma (POAG) is a progressive optic neuropathy that, left untreated, can lead to irreversible damage to the optic nerve and permanent vision loss. To date, intraocular pressure (IOP) is the only modifiable risk factor for disease progression, and topical eye-drops are currently used as the leading non-surgical glaucoma therapy. Despite the efficacy of pharmacotherapy in lowering IOP, success is ultimately defined by patient compliance and patient persistence. Ocular tolerability is a crucial factor in patient compliance and persistence; non-adherence owing to adverse effects can lead to poor control of IOP and treatment failure. Prostaglandin analogues are currently the first-line antiglaucoma agents, with a good tolerability profile and a better IOP-lowering effect compared with β-blockers. Combination therapies have also shown greater efficacy in lowering IOP compared with the individual constituents, with fewer adverse effects. Treatment should be tailored to the individual patient, with a focus on ocular tolerability and its role in adherence, compliance and vision preservation.

A Survey of Neonatal Nurses on Mydriatic Regimens Used in Neonatal Retinopathy of Prematurity Eye Examinations

2021 ◽  
Author(s):  
Lisa Kremer ◽  
David Reith ◽  
Natalie J. Medlicott ◽  
Mary J. Sime ◽  
Liza Edmonds ◽  
...  
Keyword(s):  
New Zealand ◽  
Adverse Effects ◽  
Retinopathy Of Prematurity ◽  
Adverse Drug Events ◽  
Preterm Neonates ◽  
Eye Drops ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Aotearoa New Zealand ◽  
Adult Dose

Objective This study was aimed to determine mydriatic regimen(s) used in neonatal units in Aotearoa New Zealand (NZ) and Australia and to estimate the frequency of adverse drug events following mydriatic administration in preterm neonates. Study Design A cross-sectional survey was sent to neonatal nursing staff listed in the Australian and New Zealand Neonatal Network contact list. Participants were asked to state what mydriatic regimen they use, and to estimate the frequency of adverse drug events when eye drops were administered for retinopathy of prematurity eye examinations (ROPEE). Results Thirteen different mydriatic regimens were identified; phenylephrine 2.5% and cyclopentolate 0.5% (1 standard drop of each) was the most commonly used regimen. Two of the regimens exceeded adult doses and five regimens included a mydriatic that is equivalent to an adult dose. Following mydriatic instillation, the three most common adverse effects were apnea, tachycardia, and periorbital pallor. Conclusion Low-concentration single-microdrop regimens are currently in use and resulting in successful ROPEE, yet doses exceeding adult doses are in use throughout Aotearoa NZ and Australian units. We know from this dataset that neonates are experiencing unwanted and potentially preventable, adverse effects associated with mydriatics, and every effort should be made to minimize this risk. Key Points

scholarly journals Is it possible to identify compliance and adherence to therapy? Experts opinion

2020 ◽  
Vol 23 (3) ◽  
pp. 174-181
Author(s):  
Tatiana V. Sokolova ◽  
M. S. Davidenko ◽  
Alеxandr P. Malyarchuk
Keyword(s):  
Patient Compliance ◽  
Medical Literature ◽  
Disease Patient ◽  
Adherence To Therapy

Today, the terms compliance and adherence are often used in the medical literature. The problem of patient compliance/adherence to therapy is the basis of the physicianpatient relationship complex. The study of this complex is used by specialists with various profiles to assess the effectiveness of therapy. This publication has studied the opinion of specialists when answering the following question: Is it possible to identify compliance and adherence to therapy? The factors determining the compliance/adherence of patients to treatment regardless of nosological forms of the disease are systematized. A total of four groups of factors of nonadherence to therapy associated with the disease, patient, doctor, and treatment were identified in this study.

E

2020 ◽  
pp. 275-307
Author(s):  
Sean Ainsworth
Keyword(s):  
Adverse Effects ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Recombinant Human Erythropoietin ◽  
Eye Drops ◽  
Enzyme Replacement ◽  
Maternal Treatment ◽  
Human Erythropoietin

This chapter presents information on neonatal drugs that begin with E, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Enemas, laxatives, and suppositories, Enoxaparin, Enzyme replacement therapy, Epoetin (recombinant human erythropoietin = rEPO), Epoprostenol and other prostanoids (iloprost and teoprostinil), Erythromycin, Esomeprazole, Ethambutol, and Eye drops (and ointments)

scholarly journals Acute red eye following the use of steroid eye drops by patients seen at the eye clinic, department of ophthalmology, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital Amaku – Awka, South Eastern Nigeria: Case series

2021 ◽  
Vol 2 (1) ◽  
pp. 01-07
Author(s):  
Ochiogu Bernard Chukwunonyerem ◽  
Udeaja Anthonia Chinyelu ◽  
Ughachukwu Peter Olisa
Keyword(s):  
Adverse Effects ◽  
Topical Steroid ◽  
Case Series ◽  
University Teaching ◽  
Eye Drops ◽  
Steroid Use ◽  
Important Group ◽  
Red Eye ◽  
Department Of Ophthalmology ◽  
Eye Clinic

Five cases (one male, four females aged between 32-65 years) of acute painful red eye following application of steroid eye drops have been presented. Their presentation followed a similar trend viz: sudden painful eyes, redness, tearing, photophobia, tenderness, and blepharospasm following topical steroid eye use. There was immediate relief within an hour of instillation of atropine 1% eye drop and full recovery after two weeks of presentation following further treatment with atropine 1% eye drop, tablet paracetamol, chloramphenicol eye drop and flurbiprofen eye drop. Steroids are important group of drugs that are employed in the management of many medical conditions. When used properly, they bring good results most of the time. Acute red eye was observed in this case series following topical steroid use on the eyes and the patients need to be educated on the proper use of this group of drugs so as to reduce its adverse effects.

Prostaglandin analogues: A double-edged sword in orbital glaucoma disease management

2020 ◽  
pp. 112067212090529
Author(s):  
Varajini Joganathan ◽  
Paul S Cannon ◽  
Karl Mercieca
Keyword(s):  
Intraocular Pressure ◽  
Adverse Effects ◽  
Ocular Hypertension ◽  
Pressure Rise ◽  
Eye Drops ◽  
Prostaglandin Analogue ◽  
Prostaglandin Analogues ◽  
Patient Reported ◽  
The Aesthetic ◽  
Orbital Disease

Introduction: The authors describe benefits of the recognised adverse effects of prostaglandin analogues on periocular structures in patients with unilateral proptosis and intraocular pressure rise. This case points to intentional consideration of prostaglandin analogue therapy in this selected cohort of patients with secondary ocular hypertension and proptosis. Case description: A 70-year-old gentleman who presented with a 1-week history of a red and painful right eye associated with tortuous and dilated episcleral blood vessels. Visual acuity was unaffected. A diagnosis of idiopathic orbital inflammatory disease was made by extraocular muscle biopsy. Two weeks later, the patient presented with worsening pain, reduced vision and raised intraocular pressure. The secondary ocular hypertension was successfully treated with topical preserved eye drops, including latanoprost, a prostaglandin analogue. Over 6 months, the patient developed drop intolerance and punctate keratopathy leading to therapy non-adherence. Interestingly, the patient reported improvement in periocular appearance related to prostaglandin-associated periorbitopathy. Ocular surface disease and intraocular pressures were subsequently managed with preservative-free eye drops. Conclusion: Secondary ocular hypertension is not an uncommon consequence of orbital disease. Prostaglandin analogue can act as a double-edged sword in the management of raised intraocular pressure by reducing eye pressure at the cost of developing adverse effects of prostaglandin-associated periorbitopathy. These adverse effects however can be beneficial in the aesthetic rehabilitation of proptosis and associated exposure keratopathy in patients with unilateral orbital disease and probably should be sought as first line treatment in those with proptosis and raised intraocular pressure.

Dermatological adverse effects of anti‐glaucoma eye drops: a review

2022 ◽  
Author(s):  
Alexandra Patchinsky ◽  
Nadine Petitpain ◽  
Pierre Gillet ◽  
Karine Angioi‐Duprez ◽  
Jean Luc Schmutz ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Eye Drops

scholarly journals Etonogestrel contraceptive implant (Implanon): analysis of patient compliance and adverse effects in the breastfeeding period

2010 ◽  
Vol 11 (3) ◽  
pp. 141-144 ◽  
Author(s):  
Candan Iltemir Duvan ◽  
Elif Gozdemir ◽  
Ikbal Kaygusuz ◽  
Zeynep Kamalak ◽  
Nilgun Ozturk Turhan
Keyword(s):  
Adverse Effects ◽  
Patient Compliance ◽  
Contraceptive Implant

A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation

2020 ◽  
pp. bjophthalmol-2020-315911
Author(s):  
Chee Wai Wong ◽  
Josbert M Metselaar ◽  
Gert Storm ◽  
Tina T Wong
Keyword(s):  
Drug Delivery ◽  
Clinical Trials ◽  
Patient Compliance ◽  
Anterior Segment ◽  
Topical Steroid ◽  
Medical Problem ◽  
Ocular Tissue ◽  
Cystoid Macular Oedema ◽  
Topical Steroids ◽  
Eye Drops

Ocular anterior segment inflammation is a medical problem that is seen in cases of cataract surgery and non-infectious anterior uveitis. Inadequately treated anterior segment inflammation can lead to sight-threatening conditions such as corneal oedema, glaucoma and cystoid macular oedema. The mainstay of treatment for anterior segment inflammation is topical steroid eye-drops. However, several drawbacks limit the critical value of this treatment, including low bioavailability, poor patient compliance, relatively difficult administration manner and risk of blurring of vision and ocular irritation. A drug delivery system (DDS) that can provide increased bioavailability and sustained delivery while being specifically targeted towards inflamed ocular tissue can potentially replace daily eye-drops as the gold standard for management of anterior segment inflammation. The various DDS for anti-inflammatory drugs for the treatment of anterior segment inflammation are listed and summarised in this review, with a focus on commercially available products and those in clinical trials. Dextenza, INVELTYS, Dexycu and Bromsite are examples of DDS that have enjoyed success in clinical trials leading to FDA approval. Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised.

scholarly journals A multicenter Spanish study of atropine 0.01% in childhood myopia progression

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Inés Pérez-Flores ◽  
Beatríz Macías-Murelaga ◽  
Jesús Barrio-Barrio ◽  
Inés Pérez Flores ◽  
Marta Valcárcel Vizcaíno ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Effects ◽  
Pupil Diameter ◽  
Pediatric Population ◽  
Anterior Chamber Depth ◽  
Eye Drops ◽  
Myopia Progression ◽  
Telephone Consultation ◽  
Progression Risk

AbstractTo evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between − 2.00 D to − 6.00 D, astigmatism < 1.50 D and documented previous annual progression greater than − 0.5 D (cycloplegic spherical equivalent, SE) were included. Once nightly atropine 0.01% eye drops in each eye were prescribed to all participants for 12 months. Age, gender, ethnicity and iris color were registered. All patients underwent the same follow-up protocol in every center: baseline visit, telephone consultation 2 weeks later and office controls at 4, 8 and 12 months. At each visit, best-corrected visual acuity, and cycloplegic autorefraction were assessed. Axial length (AL), anterior chamber depth and pupil diameter were measured on an IOL Master (Carl Zeiss Meditec, Inc, Dublin, CA). Adverse effects were registered in a specific questionnaire. Mean changes in cycloplegic SE and AL in the 12 months follow-up were analyzed. SE progression during treatment was compared with the SE progression in the year before enrollment for each patient. Correlation between SE and AL, and annual progression distribution were evaluated. Progression risk factors were analyzed by multivariate logistic regression analyses. Of the 105 recruited children, 92 completed the treatment. Mean SE and AL changes were − 0.44 ± 0.41 D and 0.27 ± 0.20 mm respectively. Mean SE progression was lower than the year before treatment (− 0.44 ± 0.41 D versus − 1.01 ± 0.38 D; p < 0.0001). An inverse correlation between SE progression and AL progression (r: − 0.42; p < 0.0001) was found. Fifty-seven patients (62%) had a SE progression less than − 0.50 D. No risk factors associated with progression could be identified in multivariate analyses. Mean pupil diameter increment at 12-months visit was 0.74 ± 1.76 mm. The adverse effects were mild and infrequent, and decreased over the time. Atropine 0.01% is effective and safe for myopia progression control in a multicentric Spanish children cohort. We believe this efficacy might be extensible to the myopic pediatric population from Western countries with similar social and demographic features. More studies about myopia progression risk factors among atropine treated patients are needed.

Sign in / Sign up

Export Citation Format

Share Document